Spruce Biosciences (SPRB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
The annual meeting is scheduled for May 21, 2026, to be held virtually, with voting on director elections, auditor ratification, executive compensation, and say-on-pay frequency.
A 1:75 reverse stock split was effected in August 2025, impacting all share amounts and equity awards.
The record date for voting is March 24, 2026, with 1,372,278 shares outstanding.
Voting matters and shareholder proposals
Shareholders will vote to elect three Class III directors for terms expiring in 2029.
Ratification of BDO USA, P.C. as independent auditor for fiscal 2026 is on the agenda.
Advisory votes will be held on executive compensation and the frequency of future say-on-pay votes, with the board recommending annual votes.
No other matters are expected, but proxies may vote on additional business if raised.
Board of directors and corporate governance
The board consists of seven members, divided into three classes with staggered three-year terms.
A majority of directors are independent per Nasdaq rules; the board is chaired by an independent director.
Committees include Audit, Compensation, and Nominating, all composed of independent directors.
The board met 12 times in the last fiscal year, with regular executive sessions for non-employee directors.
Stockholders can communicate with the board via a formal process.
Latest events from Spruce Biosciences
- Annual meeting to elect directors, ratify auditor, and vote on executive pay and its frequency.SPRB
Proxy filing9 Apr 2026 - Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum.SPRB
The Citizens Life Sciences Conference 202610 Mar 2026 - FDA supports accelerated approval; commercial and financial plans are on track for launch.SPRB
Leerink Global Healthcare Conference 20269 Mar 2026 - TA-ERT program progresses toward BLA submission as net loss narrows and cash runway extends.SPRB
Q4 20259 Mar 2026 - TA-ERT is BLA-ready for MPS IIIB, with durable efficacy, safety, and strong market potential.SPRB
Corporate presentation9 Mar 2026 - TA-ERT targets MPS IIIB with durable efficacy, aiming for FDA approval and $1B+ peak sales.SPRB
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Key CAH and PCOS data readouts expected in Q3, with a depression study launching in Q4.SPRB
Jefferies Global Healthcare Conference13 Feb 2026 - Q4 data from CAH and PCOS trials will shape future strategy, with MDD and partnerships advancing.SPRB
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - December data from key CAH studies will shape next steps for tildacerfont and future trials.SPRB
Guggenheim Inaugural Global Healthcare Innovation Conference15 Jan 2026